Impact Factor
3.85
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.90
936 total citations
h5-index
37
h5 depth signal
Cited share
76.1%
150 of 197
Total citations
936
Citation footprint
Metric signal
5.49
External metric anchor
Self-citation
13.7%
128 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Italy
241
United States
204
United Kingdom
166
Sweden
140
Germany
117
Citing Fields of Research
Cardiology
723
Diabetes
141
Lipids
79
Pharmacology & Toxicology
49
Hematology
41
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
990
Articles tracked across the journal lifetime
Indexed publication set
197
150 cited publications
Last 12 months
101
8.4 publications/month
Open access share
100.0%
101 OA publications in the last year
Leading citing country
Italy
241 citing publications
Leading citing field
Cardiology
723 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v2n1, Jan. 2016-
v2n1, Jan. 2016- ; Selected citations only before this date
Research Focus & Classification
Indexed Subjects
Cardiology
Issuing & Sponsoring Bodies
issuing body
European Society of Cardiology. Cardiovascular Pharmacotherapy Working Group
Broad Categories
Cardiology
Drug Therapy
Pharmacology
Vascular Diseases
MeSH Descriptors
Cardiovascular Agents
Cardiovascular Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/ehjcvp/pvag091
Open DOI
Dapagliflozin in phenotypically stratified HFpEF without myocardial fibrosis: the STADIA-HFpEF randomized crossover trial
Aims: Heart failure with preserved ejection fraction(HFpEF) is characterized by increased diastolic left ventricular(LV) stiffness resulting from variable contributions of myocardial extracellular matrix(ECM) remodeling and titin-based c...
02
DOI 10.1093/ehjcvp/pvag092
Open DOI
Repositioning Vericiguat after VICTOR: Towards a Risk- and Timing-Based Framework in Contemporary HFrEF
Vericiguat, an oral soluble guanylate cyclase stimulator, provides a mechanistically distinct approach to reducing residual risk in heart failure with reduced ejection fraction (HFrEF). The VICTORIA trial demonstrated a reduction in card...
03
04
05
06
DOI 10.1093/ehjcvp/pvag089
Open DOI
Analysis and Interpretation of a Hierarchical Outcome in a Small Pilot Randomized Trial: An Example in the CORTAHF Trial
Aims: Hierarchical composite endpoints (HCE) analyzed using generalized pairwise comparisons (GPC) have been increasingly adopted in cardiovascular trials. Stratified, but not covariate-adjusted, win statistics have been frequently prese...
07
DOI 10.1093/ehjcvp/pvag085
Open DOI
The LIBREXIA-ACS trial: new fuel for debate?
08
DOI 10.1093/ehjcvp/pvag082
Open DOI
Statins for primary prevention in the elderly
09
DOI 10.1093/ehjcvp/pvag084
Open DOI
Average daily ischaemic and bleeding risk following acute coronary syndrome: insights from the FORCE-ACS registry
Aims: To characterize ischaemic and bleeding events and compare the average daily ischaemic rate (ADIR) and average daily bleeding rate (ADBR) during 3 years post-acute coronary syndrome (ACS). Methods and results: Data were derived from...
10
Bibliographical & Catalog Notes
Also issued online.
Companion publication to: European heart journal.
complemented by (work): European heart journal 0195-668X (DLC)sn 79009215 (OCoLC)5585193.